Medical Devices

Amid mixed results, Kimball Electronics heads to key investor conferences with a new growth story fueled by medical tech and a raised financial outlook.

With a strong cash position and new leadership, Artiva pivots its AlloNK® cell therapy to autoimmune disease, targeting a pivotal trial for RA in 2026.

Dallas Nephrology Associates earns its second Burl Osborne Award, a testament to its sustained, innovative commitment to fighting kidney disease in Texas.

A new fellowship at the Institut Pasteur aims to revolutionize public health by training scientists in what its founder calls the '3Ms': Money, Management, and Medicine.

A leading Idaho dental group is up for sale, highlighting the growing trend of private equity investment and consolidation in local healthcare services.

The xIoT security firm is a finalist for Best Vulnerability Management Solution, while its CEO is up for Security Executive of the Year.

An Alabama firm's key regulatory filing for a critical drug component could accelerate the development of cheaper cancer supportive care biosimilars.

PainTEQ's landmark deal, crowned 'Deal of the Year,' showcases a new model for medtech growth and its patient-first mission in pain management.

New analysis of Phase 1 data for NKGen Biotech’s troculeucel suggests cognitive benefits, offering a potential new weapon against neuroinflammation.

Promising results for bladder cancer therapy TARA-002, key FDA designations, and a $198M cash runway position Protara for a pivotal year.

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.

A new drug targeting the root cause of deadly device infections enters a pivotal trial, offering hope to millions and challenging a $20 billion problem.

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

A $12.2M impairment charge pushed Ultralife to a net loss, but rising sales, a soaring backlog, and new efficiencies tell a far more positive story.

With its CAR-T therapy achieving franchise profitability and treating 10,000 patients, Legend Biotech eyes overall profit and next-gen cancer treatments.

Promising clinical trial results for Insulet's fully closed-loop system aim to revolutionize daily management for millions with Type 2 diabetes.

A groundbreaking analysis quantifies the hidden costs of common IV failures, showing how early detection technology can save lives and boost hospital margins.

Middle and high schoolers are building AI to aid surgery and streamline recycling, signaling a major shift from college prep to real-world innovation.

Celebrating 80 years, Aveeno renews its foundational ties with Mayo Clinic, launching a new era of oat science research for compromised skin.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.